Cagrilintide 5mg + Semaglutide 5mg Blend

This blend combines the amylin analogue Cagrilintide with the GLP-1 agonist Semaglutide (5mg each) for enhanced metabolic and appetite-suppressing effects. Research suggests dual pathway activation may produce superior weight loss and glycemic control compared to single agents. This combination is investigated for advanced metabolic research applications.